clarithromycin has been researched along with rifapentine in 11 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 5 (45.45) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (45.45) | 24.3611 |
| 2020's | 1 (9.09) | 2.80 |
| Authors | Studies |
|---|---|
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Cynamon, MH; Klemens, SP; Swenson, CE | 1 |
| Gikas, A; Grosset, J; Perronne, C; Pocidalo, JJ; Truffot-Pernot, C; Vilde, JL | 1 |
| Cynamon, MH; Klemens, SP | 1 |
| Bryskier, A; Hoppe, JE | 1 |
| Ahmad, Z; Almeida, D; Converse, PJ; Dooley, KE; Grosset, JH; Nuermberger, EL | 1 |
| Aubry, A; Chauffour, A; Jarlier, V; Robert, J; Veziris, N | 1 |
| Almeida, DV; Converse, PJ; Nuermberger, EL; Tyagi, S; Xu, J | 1 |
| Adams, LB; Collins, JH; Hagge, DA; Lahiri, R; Lenz, SM; Ray, NA | 1 |
1 review(s) available for clarithromycin and rifapentine
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 trial(s) available for clarithromycin and rifapentine
| Article | Year |
|---|---|
Researchers find new drugs to fight MAC.
Topics: AIDS-Related Opportunistic Infections; Animals; Antitubercular Agents; CD4 Lymphocyte Count; Clarithromycin; Half-Life; Humans; Mycobacterium avium-intracellulare Infection; Placebos; Randomized Controlled Trials as Topic; Rifabutin; Rifampin | 1995 |
9 other study(ies) available for clarithromycin and rifapentine
| Article | Year |
|---|---|
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
TLC G-65 in combination with other agents in the therapy of Mycobacterium avium infection in beige mice.
Topics: Amikacin; Animals; Antitubercular Agents; Clarithromycin; Clofazimine; Culture Media; Drug Therapy, Combination; Erythromycin; Ethambutol; Gentamicins; Liposomes; Mice; Mice, Inbred C57BL; Mycobacterium avium; Rifampin; Tuberculosis | 1992 |
Activities of sparfloxacin, azithromycin, temafloxacin, and rifapentine compared with that of clarithromycin against multiplication of Mycobacterium avium complex within human macrophages.
Topics: 4-Quinolones; Acquired Immunodeficiency Syndrome; Anti-Bacterial Agents; Azithromycin; Cell Division; Clarithromycin; Erythromycin; Fluoroquinolones; Humans; In Vitro Techniques; Leprostatic Agents; Macrophages; Microbial Sensitivity Tests; Mycobacterium avium Complex; Quinolones; Rifampin | 1991 |
Intermittent azithromycin for treatment of Mycobacterium avium infection in beige mice.
Topics: Animals; Azithromycin; Clarithromycin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Male; Mice; Mice, Inbred C57BL; Mycobacterium avium; Rifampin; Tuberculosis | 1994 |
In vitro susceptibilities of Bordetella pertussis and Bordetella parapertussis to two ketolides (HMR 3004 and HMR 3647), four macrolides (azithromycin, clarithromycin, erythromycin A, and roxithromycin), and two ansamycins (rifampin and rifapentine).
Topics: Anti-Bacterial Agents; Azithromycin; Bordetella; Bordetella pertussis; Clarithromycin; Erythromycin; Ketolides; Macrolides; Microbial Sensitivity Tests; Rifabutin; Rifampin; Roxithromycin | 1998 |
Activities of rifampin, Rifapentine and clarithromycin alone and in combination against mycobacterium ulcerans disease in mice.
Topics: Animals; Anti-Bacterial Agents; Buruli Ulcer; Clarithromycin; Disease Models, Animal; Drug Therapy, Combination; Female; Mice; Mice, Inbred BALB C; Mycobacterium ulcerans; Rifampin; Treatment Outcome | 2011 |
Sterilizing Activity of Fully Oral Intermittent Regimens against Mycobacterium Ulcerans Infection in Mice.
Topics: Animals; Anti-Bacterial Agents; Buruli Ulcer; Clarithromycin; Diarylquinolines; Drug Therapy, Combination; Female; Fluoroquinolones; Humans; Mice; Mice, Inbred BALB C; Moxifloxacin; Mycobacterium ulcerans; Rifampin | 2016 |
Shortening Buruli Ulcer Treatment with Combination Therapy Targeting the Respiratory Chain and Exploiting Mycobacterium ulcerans Gene Decay.
Topics: Animals; Anti-Bacterial Agents; Bacterial Load; Buruli Ulcer; Clarithromycin; Clofazimine; Disease Models, Animal; Drug Resistance, Bacterial; Drug Therapy, Combination; Electron Transport; Humans; Imidazoles; Mice, Inbred BALB C; Microbial Sensitivity Tests; Mycobacterium ulcerans; Piperidines; Pyridines; Rifampin; Streptomycin | 2019 |
Post-exposure prophylaxis (PEP) efficacy of rifampin, rifapentine, moxifloxacin, minocycline, and clarithromycin in a susceptible-subclinical model of leprosy.
Topics: Animals; Asymptomatic Infections; Bacterial Load; Clarithromycin; Drug Combinations; Leprostatic Agents; Leprosy; Mice; Mice, Nude; Minocycline; Moxifloxacin; Mycobacterium leprae; Post-Exposure Prophylaxis; Rifampin | 2020 |